Investors’ appetite for obesity treatments is proving hard to satisfy. Swiss pharmaceuticals giant Roche Holding AG has just agreed to pay up to $3.1 billion for a US biotech working on several early-stage weight-loss drugs. Biotech M&A often makes investors nauseous, but in this area they are giving buyers the benefit of the doubt. The gain in Roche’s market value on Monday exceeded the purchase price.

You can understand the enthusiasm. Bloomberg Intelligence reckons the market for anti-obesity treatments could be $44 billion in 2030. Other analysts say $100 billion. Novo Nordisk A/S’s Ozempic made the Danish pharmaceutical firm Europe’s most valuable company. The other leader in the field, Indianapolis-based Eli Lilly & Co., has seen its stock gain 60% so far in 2023. This was a relatively niche investment theme until this year.

QOSHE - Investors Can’t Help Gorging on Anti-Obesity Drugs - Chris Hughes
menu_open
Columnists Actual . Favourites . Archive
We use cookies to provide some features and experiences in QOSHE

More information  .  Close
Aa Aa Aa
- A +

Investors Can’t Help Gorging on Anti-Obesity Drugs

5 0
04.12.2023

Investors’ appetite for obesity treatments is proving hard to satisfy. Swiss pharmaceuticals giant Roche Holding AG has just agreed to pay up to $3.1 billion for a US biotech working on several early-stage........

© Bloomberg

Get it on Google Play